SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

17 May 2024 Evaluate
A slight decline in the revenue of Rs. 5466.30 millions was seen for the March 2024 quarter as against Rs. 5726.40 millions during year-ago period.The company has announced a 37.96% increase in its profits to Rs . 1788.60  millions for the  quarter ended March 2024 compared to Rs. 1296.50 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2645.60 millions from 2132.50 millions in the quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 5466.30 5726.40 -4.54 21931.70 24247.60 -9.55 21931.70 24247.60 -9.55
Other Income 751.30 313.80 139.42 1805.10 1010.50 78.63 1805.10 1010.50 78.63
PBIDT 2645.60 2132.50 24.06 8158.10 9099.10 -10.34 8158.10 9099.10 -10.34
Interest 69.50 25.30 174.70 154.10 133.90 15.09 154.10 133.90 15.09
PBDT 2576.10 1911.30 34.78 8083.50 9295.20 -13.04 8083.50 9295.20 -13.04
Depreciation 137.50 264.10 -47.94 622.80 1055.10 -40.97 622.80 1055.10 -40.97
PBT 2438.60 1647.20 48.05 7460.70 8240.10 -9.46 7460.70 8240.10 -9.46
TAX 650.00 350.70 85.34 1947.40 2000.80 -2.67 1947.40 2000.80 -2.67
Deferred Tax 163.10 -315.30 -151.73 361.10 -519.10 -169.56 361.10 -519.10 -169.56
PAT 1788.60 1296.50 37.96 5513.30 6239.30 -11.64 5513.30 6239.30 -11.64
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 48.40 37.24 29.96 37.20 37.53 -0.87 37.20 37.53 -0.87

Pfizer Share Price

4734.55 -47.55 (-0.99%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×